# Helios Technologies, Inc.: financial statements, quarterly

HLIO · NYSE · CIK 1024795 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 30

Pages: [Overview](/companies/hlio.md) · [Financials](/companies/hlio/financials.md) · [Filings](/companies/hlio/filings.md) · [Insiders](/companies/hlio/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/hlio/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-30) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q4 FY2024 (2024-12-28) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q4 FY2025 (2026-01-03) | Q1 FY2026 (2026-04-04) | Q2 FY2026 (2026-07-04) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [201](/filings/0000950170-24-122433.md) | [193 d](/filings/0001193125-26-087747.md) | [212](/filings/0000950170-25-065585.md) | [220](/filings/0000950170-25-103231.md) | [195](/filings/0001193125-25-264784.md) | [180 d](/filings/0001193125-26-087747.md) | [196](/filings/0001193125-26-219232.md) | [213](/filings/0001193125-26-344521.md) | [220](/filings/0001193125-25-264784.md) | [211 d](/filings/0001193125-26-087747.md) | [228](/filings/0001193125-26-219232.md) | [232](/filings/0001193125-26-344521.md) |
| Cost of revenue | $m | [142](/filings/0000950170-24-122433.md) | [138 d](/filings/0001193125-26-087747.md) | [145](/filings/0000950170-25-065585.md) | [149](/filings/0000950170-25-103231.md) | [134](/filings/0001193125-25-264784.md) | [126 d](/filings/0001193125-26-087747.md) | [136](/filings/0001193125-26-219232.md) | [145](/filings/0001193125-26-344521.md) | [147](/filings/0001193125-25-264784.md) | [140 d](/filings/0001193125-26-087747.md) | [154](/filings/0001193125-26-219232.md) | [152](/filings/0001193125-26-344521.md) |
| Gross profit | $m | [59.7](/filings/0000950170-24-122433.md) | [55.2 d](/filings/0001193125-26-087747.md) | [67.2](/filings/0000950170-25-065585.md) | [70.6](/filings/0000950170-25-103231.md) | [60.5](/filings/0001193125-25-264784.md) | [54.0 d](/filings/0001193125-26-087747.md) | [59.9](/filings/0001193125-26-219232.md) | [67.5](/filings/0001193125-26-344521.md) | [73.0](/filings/0001193125-25-264784.md) | [70.9 d](/filings/0001193125-26-087747.md) | [74.9](/filings/0001193125-26-219232.md) | [80.2](/filings/0001193125-26-344521.md) |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | [37.7](/filings/0000950170-24-122433.md) | [35.1 d](/filings/0001193125-26-087747.md) | [39.0](/filings/0000950170-25-065585.md) | [36.7](/filings/0000950170-25-103231.md) | [30.4](/filings/0001193125-25-264784.md) | [32.8 d](/filings/0001193125-26-087747.md) | [34.6](/filings/0001193125-26-219232.md) | [37.3](/filings/0001193125-26-344521.md) | [38.2](/filings/0001193125-25-264784.md) | [37.6 d](/filings/0001193125-26-087747.md) | [37.4](/filings/0001193125-26-219232.md) | [40.2](/filings/0001193125-26-344521.md) |
| Operating income | $m | [13.8](/filings/0000950170-24-122433.md) | [11.9 d](/filings/0001193125-26-087747.md) | [20.3](/filings/0000950170-25-065585.md) | [26.0](/filings/0000950170-25-103231.md) | [22.2](/filings/0001193125-25-264784.md) | [13.3 d](/filings/0001193125-26-087747.md) | [17.0](/filings/0001193125-26-219232.md) | [21.9](/filings/0001193125-26-344521.md) | [1.3](/filings/0001193125-25-264784.md) | [25.7 d](/filings/0001193125-26-087747.md) | [29.9](/filings/0001193125-26-219232.md) | [32.5](/filings/0001193125-26-344521.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [1.5](/filings/0000950170-24-122433.md) | [1.0 d](/filings/0001193125-26-087747.md) | [2.8](/filings/0000950170-25-065585.md) | [4.0](/filings/0000950170-25-103231.md) | [1.9](/filings/0001193125-25-264784.md) | [2.8 d](/filings/0001193125-26-087747.md) | [2.2](/filings/0001193125-26-219232.md) | [3.5](/filings/0001193125-26-344521.md) | [2.5](/filings/0001193125-25-264784.md) | [5.7 d](/filings/0001193125-26-087747.md) | [5.9](/filings/0001193125-26-219232.md) | [6.2](/filings/0001193125-26-344521.md) |
| Net income | $m | [3.5](/filings/0000950170-24-122433.md) | [3.4 d](/filings/0001193125-26-087747.md) | [9.2](/filings/0000950170-25-065585.md) | [13.6](/filings/0000950170-25-103231.md) | [11.4](/filings/0001193125-25-264784.md) | [4.8 d](/filings/0001193125-26-087747.md) | [7.3](/filings/0001193125-26-219232.md) | [11.4](/filings/0001193125-26-344521.md) | [10.3](/filings/0001193125-25-264784.md) | [19.5 d](/filings/0001193125-26-087747.md) | [19.7](/filings/0001193125-26-219232.md) | [21.9](/filings/0001193125-26-344521.md) |
| Diluted EPS | $ per share | [0.11](/filings/0000950170-24-122433.md) | not reported | [0.28](/filings/0000950170-25-065585.md) | [0.41](/filings/0000950170-25-103231.md) | [0.34](/filings/0001193125-25-264784.md) | not reported | [0.22](/filings/0001193125-26-219232.md) | [0.34](/filings/0001193125-26-344521.md) | [0.31](/filings/0001193125-25-264784.md) | not reported | [0.59](/filings/0001193125-26-219232.md) | [0.66](/filings/0001193125-26-344521.md) |
| Basic EPS | $ per share | [0.11](/filings/0000950170-24-122433.md) | not reported | [0.28](/filings/0000950170-25-065585.md) | [0.41](/filings/0000950170-25-103231.md) | [0.34](/filings/0001193125-25-264784.md) | not reported | [0.22](/filings/0001193125-26-219232.md) | [0.34](/filings/0001193125-26-344521.md) | [0.31](/filings/0001193125-25-264784.md) | not reported | [0.60](/filings/0001193125-26-219232.md) | [0.66](/filings/0001193125-26-344521.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: not reported
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-30) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | FY2024 (2024-12-28) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | FY2025 (2026-01-03) | Q1 FY2026 (2026-04-04) | Q2 FY2026 (2026-07-04) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [35.2](/filings/0000950170-23-059853.md) | [32.4](/filings/0000950170-25-026703.md) | [37.3](/filings/0000950170-24-056684.md) | [45.0](/filings/0000950170-24-091785.md) | [46.7](/filings/0000950170-24-122433.md) | [44.1](/filings/0001193125-26-087747.md) | [45.9](/filings/0000950170-25-065585.md) | [53.0](/filings/0000950170-25-103231.md) | [54.9](/filings/0001193125-25-264784.md) | [73.0](/filings/0001193125-26-344521.md) | [64.2](/filings/0001193125-26-219232.md) | [68.0](/filings/0001193125-26-344521.md) |
| Current assets | $m | [410](/filings/0000950170-23-059853.md) | [397](/filings/0000950170-25-026703.md) | [409](/filings/0000950170-24-056684.md) | [423](/filings/0000950170-24-091785.md) | [406](/filings/0000950170-24-122433.md) | [384](/filings/0001193125-26-087747.md) | [396](/filings/0000950170-25-065585.md) | [439](/filings/0000950170-25-103231.md) | [449](/filings/0001193125-25-264784.md) | [415](/filings/0001193125-26-344521.md) | [427](/filings/0001193125-26-219232.md) | [439](/filings/0001193125-26-344521.md) |
| Total assets | $m | [1,591](/filings/0000950170-23-059853.md) | [1,590](/filings/0001193125-26-087747.md) | [1,584](/filings/0000950170-24-056684.md) | [1,581](/filings/0000950170-24-091785.md) | [1,572](/filings/0000950170-24-122433.md) | [1,505](/filings/0001193125-26-087747.md) | [1,526](/filings/0000950170-25-065585.md) | [1,582](/filings/0000950170-25-103231.md) | [1,556](/filings/0001193125-25-264784.md) | [1,515](/filings/0001193125-26-344521.md) | [1,512](/filings/0001193125-26-219232.md) | [1,516](/filings/0001193125-26-344521.md) |
| Current liabilities | $m | [136](/filings/0000950170-23-059853.md) | [145](/filings/0000950170-25-026703.md) | [145](/filings/0000950170-24-056684.md) | [145](/filings/0000950170-24-091785.md) | [134](/filings/0000950170-24-122433.md) | [139](/filings/0001193125-26-087747.md) | [143](/filings/0000950170-25-065585.md) | [179](/filings/0000950170-25-103231.md) | [153](/filings/0001193125-25-264784.md) | [143](/filings/0001193125-26-344521.md) | [150](/filings/0001193125-26-219232.md) | [160](/filings/0001193125-26-344521.md) |
| Total liabilities | $m | [749](/filings/0000950170-23-059853.md) | [736](/filings/0000950170-25-026703.md) | [727](/filings/0000950170-24-056684.md) | [714](/filings/0000950170-24-091785.md) | [686](/filings/0000950170-24-122433.md) | [641](/filings/0001193125-26-087747.md) | [645](/filings/0000950170-25-065585.md) | [670](/filings/0000950170-25-103231.md) | [638](/filings/0001193125-25-264784.md) | [583](/filings/0001193125-26-344521.md) | [575](/filings/0001193125-26-219232.md) | [568](/filings/0001193125-26-344521.md) |
| Long-term debt | $m | [304](/filings/0000950170-23-059853.md) | [298](/filings/0000950170-25-026703.md) | [293](/filings/0000950170-24-056684.md) | [292](/filings/0000950170-24-091785.md) | [288](/filings/0000950170-24-122433.md) | [283](/filings/0001193125-26-087747.md) | [279](/filings/0000950170-25-065585.md) | [267](/filings/0000950170-25-103231.md) | [262](/filings/0001193125-25-264784.md) | [256](/filings/0001193125-26-344521.md) | [245](/filings/0001193125-26-219232.md) | [226](/filings/0001193125-26-344521.md) |
| Current portion of debt | $m | [21.8](/filings/0000950170-23-059853.md) | [23.2](/filings/0000950170-25-026703.md) | [23.2](/filings/0000950170-24-056684.md) | [17.2](/filings/0000950170-24-091785.md) | [17.6](/filings/0000950170-24-122433.md) | [16.0](/filings/0001193125-26-087747.md) | [16.1](/filings/0000950170-25-065585.md) | [24.5](/filings/0000950170-25-103231.md) | [18.5](/filings/0001193125-25-264784.md) | [5.4](/filings/0001193125-26-344521.md) | [0.0](/filings/0001193125-26-219232.md) | [0.0](/filings/0001193125-26-344521.md) |
| Shareholders' equity | $m | [842](/filings/0000950170-24-122433.md) | [855](/filings/0001193125-26-087747.md) | [857](/filings/0000950170-25-103231.md) | [867](/filings/0001193125-25-264784.md) | [886](/filings/0001193125-25-264784.md) | [864](/filings/0001193125-26-344521.md) | [881](/filings/0001193125-26-344521.md) | [912](/filings/0001193125-26-344521.md) | [918](/filings/0001193125-25-264784.md) | [932](/filings/0001193125-26-344521.md) | [936](/filings/0001193125-26-344521.md) | [948](/filings/0001193125-26-344521.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-30) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q4 FY2024 (2024-12-28) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q4 FY2025 (2026-01-03) | Q1 FY2026 (2026-04-04) | Q2 FY2026 (2026-07-04) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [11.8 d](/filings/0000950170-24-122433.md) | [33.7 d](/filings/0001193125-26-087747.md) | [17.8](/filings/0000950170-25-065585.md) | [33.8 d](/filings/0000950170-25-103231.md) | [34.8 d](/filings/0001193125-25-264784.md) | [35.7 d](/filings/0001193125-26-087747.md) | [19.0](/filings/0001193125-26-219232.md) | [37.0 d](/filings/0001193125-26-344521.md) | [25.3 d](/filings/0001193125-25-264784.md) | [46.0 d](/filings/0001193125-26-087747.md) | [23.9](/filings/0001193125-26-219232.md) | [41.9 d](/filings/0001193125-26-344521.md) |
| Capital expenditure | $m | [5.8](/filings/0000950170-24-122433.md) | [8.8 d](/filings/0001193125-26-087747.md) | [5.5](/filings/0000950170-25-065585.md) | [8.0](/filings/0000950170-25-103231.md) | [6.0](/filings/0001193125-25-264784.md) | [7.4 d](/filings/0001193125-26-087747.md) | [6.1](/filings/0001193125-26-219232.md) | [5.4](/filings/0001193125-26-344521.md) | [6.7](/filings/0001193125-25-264784.md) | [5.5 d](/filings/0001193125-26-087747.md) | [6.7](/filings/0001193125-26-219232.md) | [11.3](/filings/0001193125-26-344521.md) |
| Dividends paid | $m | [2.9 d](/filings/0000950170-24-122433.md) | [3.0 d](/filings/0001193125-26-087747.md) | [3.0](/filings/0000950170-25-065585.md) | [3.0 d](/filings/0000950170-25-103231.md) | [2.9 d](/filings/0001193125-25-264784.md) | [3.0 d](/filings/0001193125-26-087747.md) | [3.0](/filings/0001193125-26-219232.md) | [3.0 d](/filings/0001193125-26-344521.md) | [3.0 d](/filings/0001193125-25-264784.md) | [3.0 d](/filings/0001193125-26-087747.md) | [3.0](/filings/0001193125-26-219232.md) | [3.9 d](/filings/0001193125-26-344521.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-10-01) | Q1 FY2023 (2023-04-01) | Q2 FY2023 (2023-07-01) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q1 FY2026 (2026-04-04) | Q2 FY2026 (2026-07-04) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [32.6](/filings/0000950170-23-059853.md) | [32.7](/filings/0000950170-24-056684.md) | [32.9](/filings/0000950170-24-091785.md) | [33.1](/filings/0000950170-24-122433.md) | [33.3](/filings/0000950170-25-065585.md) | [33.3](/filings/0000950170-25-103231.md) | [33.2](/filings/0001193125-25-264784.md) | [33.4](/filings/0001193125-26-219232.md) | [33.3](/filings/0001193125-26-344521.md) | [33.3](/filings/0001193125-25-264784.md) | [33.3](/filings/0001193125-26-219232.md) | [33.2](/filings/0001193125-26-344521.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 32,950,577 at 2026-07-31, from the cover of the [10-Q filed 2026-08-11](/filings/0001193125-26-344521.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:30 ET. No prices; not investment advice.